Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,459.28 -5.34 (-0.10%) Dow
39,231.26 +80.93 (+0.21%) Nasdaq
17,629.97 -59.39 (-0.34%) Bitcoin USD
61,338.18 -2,931.22 (-4.56%) CMC Crypto 200
1,262.07 -47.64 (-3.64%)
APLS Oct 2024 80.000 call
| Previous close | 1.0700 |
| Open | 1.0700 |
| Bid | 0.0000 |
| Ask | 1.5500 |
| Strike | 80.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.0700 - 1.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Simply Wall St.Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
